Treatment targeted to the actual malignant tissue without damaging the surrounding healthy tissues. The global radioimmunotherapy market was valued at US$ 81.9 Mn in 2018 and is expected to reach US$ 132.7 Mn by the year 2026, growing at a CAGR of 6.5% during the forecast period.
Conventional cancer treatments such as chemotherapy and radiation therapy have some inherent disadvantages, such as they are not targeted to the cancer cells, and they damage the surrounding healthy tissues. Due to this, chemotherapy and radiation therapy have various side effects, including but not limited to fatigue, gastrointestinal problems, pain, and skin changes. Radioimmunotherapy involves the use of a radiolabelled monoclonal antibody to kill cancer cells. Monoclonal antibodies are specific to the antigens that are expressed in very high quantities in tumor cells and hence, only tumor cells are targeted. Additionally, the radioisotopes used are either alpha or beta emitters which have a small tissue range. (Alpha particles - 50-100µm; beta particles - about 1.5mm). This further limit the damage to the surrounding healthy tissues. Due to these advantages, the demand for radioimmunotherapy is expected to grow during the forecast period, thereby driving the market. However, Higher risk of immune mediated side-effects as compared to individual therapy and high therapy cost can restrain the growth of the market.
Get a Sample Copy @ https://www.alltheresearch.com/sample-request/323
In 2019, Nordic Nanovector ASA entered an agreement with Isotope Technologies Garching GmbH (ITG), a subsidiary of ITM Isotopen Technologien München AG. Owing to this agreement, the company procured Lutetium-177, a component of Betalutin